ArticleJournal of global health2025
Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: results from a large-scale longitudinal cohort study.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies on the correlation between leukocyte telomere length (LTL) and prostate cancer (PCa) have shown inconsistent results. We aimed to clarify this association by leveraging a large-scale prospective design and Mendelian randomisation. Methods: We enrolled a total of 229 022 male individuals from the UK Biobank (UKB) to investigate the association between LTL and PCa risk. We employed both unadjusted and covariates-adjusted Cox proportional hazards regression models to assess this relationship. We defined the primary outcome as the diagnosis of incident PCa using in-patient data and the death registry of the UK Biobank cohort. To validate the reliability of the primary findings, we conducted secondary analyses, including Mendelian randomisation. Results: The primary analysis demonstrated that longer LTL was substantially associated with higher risk of PCa, with associations remaining robust after adjusting for potential covariates (hazard ratio (HR) = 1.444; 95% confidence interval (CI) = 1.247, 1.673, P < 0.001). We observed similar results when LTL was analysed as both a continuous and categorical variable, and the association was shown to be inversely U-shaped. We further validated the association at the genetic level using Mendelian randomisation across different PCa databases, with results consistent with our primary analysis. Conclusions: Our findings offer evidence that leukocyte telomere length is an important risk factor for PCa. Further studies are needed to elucidate the underlying mechanisms linking leukocyte telomere length to PCa risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.